CL2021000197A1 - Terapia de infecciones de virus de papiloma humano de alto riesgo - Google Patents

Terapia de infecciones de virus de papiloma humano de alto riesgo

Info

Publication number
CL2021000197A1
CL2021000197A1 CL2021000197A CL2021000197A CL2021000197A1 CL 2021000197 A1 CL2021000197 A1 CL 2021000197A1 CL 2021000197 A CL2021000197 A CL 2021000197A CL 2021000197 A CL2021000197 A CL 2021000197A CL 2021000197 A1 CL2021000197 A1 CL 2021000197A1
Authority
CL
Chile
Prior art keywords
acid
human papillomavirus
therapy
composition
risk human
Prior art date
Application number
CL2021000197A
Other languages
English (en)
Spanish (es)
Inventor
Norbert Fuchs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of CL2021000197A1 publication Critical patent/CL2021000197A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2021000197A 2018-08-28 2021-01-25 Terapia de infecciones de virus de papiloma humano de alto riesgo CL2021000197A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18191289.0A EP3616693A1 (en) 2018-08-28 2018-08-28 Therapy of high-risk human papillomavirus infections

Publications (1)

Publication Number Publication Date
CL2021000197A1 true CL2021000197A1 (es) 2021-09-20

Family

ID=63442535

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021000197A CL2021000197A1 (es) 2018-08-28 2021-01-25 Terapia de infecciones de virus de papiloma humano de alto riesgo

Country Status (25)

Country Link
US (2) US20210299163A1 (https=)
EP (2) EP3616693A1 (https=)
JP (1) JP7420791B2 (https=)
CN (1) CN112584828A (https=)
AR (1) AR116027A1 (https=)
AU (1) AU2019332079B2 (https=)
BR (1) BR112021003360A2 (https=)
CA (1) CA3107691C (https=)
CL (1) CL2021000197A1 (https=)
EA (1) EA202190441A1 (https=)
ES (1) ES2958808T3 (https=)
GE (2) GEP20227432B (https=)
HR (1) HRP20231470T1 (https=)
HU (1) HUE064691T2 (https=)
IL (1) IL281080B2 (https=)
MA (1) MA53482B1 (https=)
MD (1) MD3843715T2 (https=)
MX (1) MX2021002310A (https=)
PL (1) PL3843715T3 (https=)
RS (1) RS64916B1 (https=)
SM (1) SMT202300340T1 (https=)
TW (1) TWI827652B (https=)
UA (1) UA127632C2 (https=)
WO (1) WO2020043762A1 (https=)
ZA (1) ZA202100375B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3875083A1 (en) * 2020-03-03 2021-09-08 Selo Medical GmbH Composition for use in a treatment of cervical cell abnormalities comprising selenite compound and acid
CN113304251A (zh) * 2021-03-04 2021-08-27 南京北极光生物科技有限公司 一种组合物在抗人乳头瘤病毒中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2406377C (en) 2000-05-10 2010-07-06 Okopharm Forschungs-Und Entwicklungs-Gmbh Method for reducing the surface area of silicon dioxide
AT412758B (de) 2000-06-05 2005-07-25 Vis Vitalis Lizenz & Handels Verwendung einer selenithältigen lösung zur behandlung viraler erkrankungen
AT412448B (de) * 2001-02-13 2005-03-25 Vis Vitalis Lizenz & Handels Verwendung von selenhältigen präparaten
AT412703B (de) 2001-12-04 2005-06-27 Vis Vitalis Lizenz & Handels Verwendung von selenithältigen präparaten zur topischen oder bukkalen anwendung
AT511159A1 (de) * 2011-02-16 2012-09-15 Selo Medical Gmbh Pharmazeutische zusammensetzungen enthaltend selenit- oder selenathältige verbindungen

Also Published As

Publication number Publication date
US20250281524A1 (en) 2025-09-11
JP7420791B2 (ja) 2024-01-23
HRP20231470T1 (hr) 2024-03-01
SMT202300340T1 (it) 2023-11-13
MA53482B1 (fr) 2023-11-30
EP3843715C0 (en) 2023-09-13
IL281080B2 (en) 2024-12-01
HUE064691T2 (hu) 2024-04-28
JP2021536454A (ja) 2021-12-27
EP3843715B1 (en) 2023-09-13
GEP20227432B (en) 2022-10-25
ZA202100375B (en) 2024-08-28
AU2019332079B2 (en) 2024-08-29
CA3107691C (en) 2024-10-29
MX2021002310A (es) 2021-04-28
GEAP202215586A (en) 2022-06-27
IL281080B1 (en) 2024-08-01
BR112021003360A2 (pt) 2021-05-11
AR116027A1 (es) 2021-03-25
US20210299163A1 (en) 2021-09-30
ES2958808T3 (es) 2024-02-15
IL281080A (en) 2021-04-29
TWI827652B (zh) 2024-01-01
EP3843715A1 (en) 2021-07-07
EP3616693A1 (en) 2020-03-04
PL3843715T3 (pl) 2024-02-19
CN112584828A (zh) 2021-03-30
UA127632C2 (uk) 2023-11-08
TW202023534A (zh) 2020-07-01
EA202190441A1 (ru) 2021-06-15
RS64916B1 (sr) 2023-12-29
AU2019332079A1 (en) 2021-02-11
MD3843715T2 (ro) 2023-12-31
CA3107691A1 (en) 2020-03-05
MA53482A (fr) 2021-07-07
WO2020043762A1 (en) 2020-03-05

Similar Documents

Publication Publication Date Title
Crow HPV: The global burden
CL2021000197A1 (es) Terapia de infecciones de virus de papiloma humano de alto riesgo
WO2007121894A3 (en) Hpv-18-based papillomavirus vaccine
PE20230349A1 (es) Vacunas para la papilomatosis respiratoria recurrente y metodos para usar estas
CO6341567A2 (es) Vacuna contra el virus de papiloma humano
JP2021525266A5 (https=)
CN106728648A (zh) 一种抗hpv病毒的中药配方
JP2021536454A5 (https=)
AR054259A1 (es) Vacuna contra virus de papiloma humano (hpv)
Gofur Warts of HPV infection, clinical manifestation and management: a review article
Pestrikova et al. Assessment of viral load in patients with HPV-associated cervicitis during the course of complex treatment
CO2022002493A2 (es) Nanoemulsion de ácido 18p-glicirretínico
EA202190589A1 (ru) Способ комбинированной терапии дисплазии шейки матки, ассоциированной с вирусами папилломы человека
BR112018067353A2 (pt) composição farmacêutica e uso de um composto ativo para tratar uma doença causada por vírus do gênero flavivirus em um feto de mamífero
UY39206A (es) Uso de parapoxvirus para el acondicionamiento y tratamiento de infecciones por coronavirus
Afshar et al. Clinical and Public Health Considerations for HPV Infection in Men: A Narrative Review
Alemany et al. Impact of vaccination against human papillomavirus: Towards cervical cancer elimination
Yu et al. Correlation of human papillomavirus (HPV) and HPV vaccines with male reproductive health
Tapilskaya et al. Spontaneous clearance of the human papilloma virus as a result of suppressive therapy with acyclic nucleosides of a recurrent herpes-viral infection
Munjal et al. Pandemic COVID-19 and its implications in dentistry: Overt actions to deal with covert threat
Heitmann et al. A Case of Erythema Multiforme
JP2023516153A5 (https=)
Fernandez-Ortega et al. P3. 447 Leukocyte Extract Modulates Cellular Factors Involved in HIV Infection
Kardani et al. The Epidemiology of HPV-Related Cancer Types
Beran et al. The last ten years with inosine pranobex-from an" old" therapeutic agent to vaccine research, including anti-cancer vaccines